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Mast cells are a heterogeneous group of immune cells. The simplest and commonly
accepted classification divides them in two groups according to their protease content.
We have compared the action of diverse secretagogues on bone marrow derived
(BMMC) and peritoneal (PMC) mast cells which represent classical models of mucosal
and connective tissue type mast cells in mice. Whereas, antigen stimulation of the
FcεRI receptors was similarly effective in triggering elevations of free intracellular
Ca2+ concentration ([Ca2+]i) in both BMMC and PMC, robust [Ca
2+]i rise following
Endothelin-1 stimulation was observed only in a fraction of BMMC. Leukotriene
C4 activating cysteinyl leukotriene type I receptors failed to evoke [Ca2+]i rise
in either mast cell model. Stimulation of the recently identified target of many
small-molecule drugs associated with systemic pseudo-allergic reactions, Mrgprb2,
with compound 48/80, a mast cell activator with unknown receptor studied for
many years, triggered Ca2+ oscillations in BMMC and robust [Ca2+]i rise in PMCs
similarly to that evoked by FcεRI stimulation. [Ca2+]i rise in PMC could also be
evoked by other Mrgprb2 agonists such as Tubocurarine, LL-37, and Substance P.
The extent of [Ca2+]i rise correlated with mast cell degranulation. Expression analysis
of TRPC channels as potential candidates mediating agonist evoked Ca2+ entry
revealed the presence of transcripts of all members of the TRPC subfamily of TRP
channels in PMCs. The amplitude and AUC of compound 48/80-evoked [Ca2+]i rise
was reduced by ∼20% in PMC from Trpc1/4/6−/− mice compared to Trpc1/4−/−
littermatched control mice, whereas FcεRI-evoked [Ca2+]i rise was unaltered. Whole-
cell patch clamp recordings showed that the reduction in compound 48/80-evoked
[Ca2+]i rise in Trpc1/4/6
−/− PMC was accompanied by a reduced amplitude of
Compound 48/80-induced cation currents which exhibited typical features of TRPC
currents. Together, this study demonstrates that PMC are an appropriate mast cell
model to study mechanisms of Mrgprb2 receptor-mediated mast cell activation, and
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it reveals that TRPC channels contribute at least partially to Mrgprb2-mediated mast
cellactivation but not following FcεRI stimulation. However, the channels conductingmost
of the Ca2+ entry in mast cells triggered by Mrgprb2 receptor stimulation remains to
be identified.
Keywords: mast cells degranulation, secretagogues, connective tissue type mast cells, mucosal tissue type mast
cells, TRPC channels, Mrgprb2 receptor, intracellular calcium
INTRODUCTION
Mast cells play a very important role in innate and adaptive
immunity by their capability of quick and massive release
of granules containing preformed inflammatory mediators
and proteases (1) as well as by the capability to secrete a
broad spectrum of cytokines and growth factors (2). The
canonical way of mast cell activation is their participation in
an immediate allergic reaction of anaphylactic type involving a
specific antigen-induced crosslinking of surface IgE molecules
bound to high-affinity receptors for IgE (FcεRI). However,
in clinical practice there are a lot of examples of mast cell
participation in less specific pseudoallergic reactions. Recently,
a pivotal role of a Mrgpr in initiation of such reactions was
shown (3, 4).
In addition to these pathophysiological processes, mast cells
represent a first line of immune defense against pathogens (5),
particularly parasites (6), determine immune tolerance (7) and
play an important role in wound healing (8) or angiogenesis (9).
Proteases released from mast cells are responsible for exogenous
toxin inactivation (10).
From direct measurements of mast cell degranulation it is
well-known that this process strongly depends on elevation in
the concentration of free intracellular calcium ions ([Ca2+]i)
(11). Numerous experiments demonstrate that particularly Ca2+
influx from extracellular space is indispensable for mast cell
activation [for review see (12)]. Activation of Fcε receptor for
IgE (FcεRI) stimulation by antigens is well-described as a trigger
to evoke elevation of [Ca2+]i in mast cells, but numerous other
agonists including adenosine, endothelin 1 (ET-1), Leukotriene
C4 (LTC4), lysophosphatidylcholine (LysoPC), sphingosine-1-
phosphate (S1P) or Substance P have been reported to lead
to mast cell activation in a Ca2+ dependent manner (12–14).
The receptors triggered by these agonists can either potentiate
FcεRI-mediated mast cell activation or act by themselves, and
stimulate the release of mast cell mediators, using different
signaling cascades.
Recently, Mrgprb2 was identified as the target of many
small-molecule drugs associated with systemic pseudo-allergic
reactions and as the receptor for Compound 48/80, a Ca2+
mobilizing mast cell agonist known for years (4). Already in
1974, it was reported that the intravenous administration of
Compound 48/80 in dogs triggers an increase of histamine
levels in the plasma (15), and some years later, it was shown
that Compound 48/80 induces histamine release from rat
mast cells (16). Mast cell responses elicited by either FcεRI
or Mrgprb2 stimulation differ significantly from each other
in many aspects (17, 18), and the molecular constituents of
Ca2+ entry channels leading to elevation of [Ca2+]i following
stimulation of Mrgprb2 receptors are unknown. Nevertheless,
receptor stimulation leads to a Ca2+ influx in rat peritoneal
mast cells (19). One type of channel activated by Compound
48/80 is voltage and IP3-independent with a 50 pS conductance
(20, 21). A more detailed characterization of the inward
current through these channels revealed that it has a ratio
of Ca2+ to Na+ permeability (PCa/PNa) of 0.55. All seven
members of the TRPC subgroup of Transient Receptor Potential
(TRP) channel protein family were reported to be expressed
in several types of mast cells [for review see (14, 22)]. As
TRPC channels represent receptor-operated non-selective cation
channels that can be activated by stimulation of various Gq/11-
coupled receptors, it can be speculated whether TRPCs might be
involved downstream of Mrgprb2 activation by agonists such as
compound 48/80.
Mast cells are classified according to their neutral proteases
content: TC mast cells (expressing tryptase and chymotryptic
proteinase) and T mast cells (expressing only tryptase) (23)
which are also referred as connective tissue-type and mucosal-
type mouse mast cells (24). These two distinct mast cells
types have different responsivity to different stimuli including
Compound 48/80 (25). In the presented work we investigated
mast cell activation and Ca2+ homeostasis in two classical,
well-established models of murine mast cell models: Bone
marrow derived mast cells (BMMC) and Peritoneal mast cells
(PMC)—representing primary cell models of mucosal and
connective tissue type mast cells, respectively. We performed
a systematical checkup of different mast cell secretagogues to
test their ability to evoke [Ca2+]i rise and degranulation in
BMMC and PMC. Whereas, antigen stimulation resulted in
robust [Ca2+]i rise in both BMMC and PMC, we observed
much weaker responses with all other agonists in BMMC
compared to PMC. PMC showed prominent reactions to
Compound 48/80 as well as other Mrgprb2 agonists including
Tubocurarine, LL-37 and Substance P. Thus, PMC represent
an ideal cell model for comparison of Ca2+-dependent mast
cell activation elicited by stimulation of FcεRI and by Mrgprb2
receptors. We found an expression of all members of the
TRPC protein family in PMC. Experiments using PMC isolated
from mice lacking TRPC1, TRPC4, and TRPC6 proteins
(Trpc1/4/6−/− mice) revealed a functional role of these proteins
as constituents of non-selective cation channels activated by
Mrgprb2 receptor stimulation, that contribute at least partially
to Mrgprb2 receptor-mediated [Ca2+]i rise and degranulation in
PMC mast cells.
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METHODS
Peritoneal Mast Cell (PMC) Isolation and
Culture
Male mice with C57Bl6/N genetic background at the age of 8–
14 weeks were used for our experiments. A double knockout
mouse line Trpc1/4−/− (DKO) and a triple knockout mouse line
Trpc1/4/6−/− (TKO) was generated by intercrossing mice of the
three mouse lines lacking expression of TRPC1 (26), TRPC4
(27), and TRPC6 (28), respectively. Each had been backcrossed
to the C57Bl6/N strain (Charles River) for at least 7 generations
before they were used to generate the Trpc1/4−/− (DKO)
and Trpc1/4/6−/− (TKO) knockout lines. For comparative
Ca2+ imaging experiments we used littermatched Trpc1/4/6−/−
(TKO) and Trpc1/4−/−; Trpc6+/+ (DKO) offspring derived from
intercrosses of Trpc1/4−/−; Trpc6+/− mice. Animal husbandry
and experimental procedures were performed in accordance with
local and European Union animal welfare standards.
For the isolation of PMC, peritoneal cells were washed
from the peritoneal cavity using peritoneal lavage technique
(29). Suspension of peritoneal cells isolated from 2 to 3 mice
was pooled together. Cells were centrifuged at ∼300 × g and
resuspended in RPMI Medium supplemented with 20% Fetal
Calf Serum (FCS), 1% PenStrep, 10 ng/ml IL-3, and 30 ng/ml
SCF. The cells were further cultured in 5% CO2 at 37
◦C. On
the 2nd day of cultivation all non-adherent cells were discarded.
The cells were split and transferred into a new flask on day
10. PMC were used for experiments between 14 and 16 days of
culturing. Flow cytometry analysis identified 98.5–99.5% cells to
be double-positive for FcεRI and c-Kit and could be ranked as
mast cells.
Bone Marrow Derived Mast Cells (BMMC)
Culture
Both hind paws were used to dissect femur bones. After cleaning
of the bones from connective and muscle tissues, two incisions at
distal and proximal sides of each bone were made. Bone marrow
was released by two short centrifugation steps (30 s at 5,000 rpm
and 120 s at 2,000 rpm). Bone marrow cells were cultured at 1 ×
106 cells/ml in IMDM supplemented with 10% heat-inactivated
fetal calf serum and 1% penicillin/streptomycin at 37◦C, 5% CO2.
The medium was additionally supplemented with 2 ng/ml IL-3
and 5 ng/ml SCF. The cells were split twice a week and cultured
for 6–12 weeks before the experiments (30).
Expression Analysis
RNA isolation was performed using the RNeasy Mini kit
(Qiagen) according to manufacturer’s protocol. To avoid false
signals originating from genomic DNA, on-column DNA-se
digestion was performed and intron spanning RT-PCR primers
were used. cDNA synthesis was performed with the SensiFAST
cDNA synthesis kit (Bioline) according to manufacturer’s
instructions. Primers were designed with the Roche R© online
tool and primer pairs with efficiency between 90 and 110%
were used. Quantitative expression analysis was performed using
the Universal Probe system (Roche) with the corresponding
FastStart Essential DNA Probes Master (Roche) on a LightCycler
96 Instrument (Roche). Expression levels of housekeeping genes
(Cxxc1, Aip, H3f3a) were also measured. Primer sequences and
probe number for TRPC1 were 5′-ctgaaggatgtgcgagaggt-3′ (fw)
and 5′-cacgccagcaagaaaagc-3′ (rev), for TRPC2 were 5′-tccttg
tcttcctcggagtc-3′ (fw) and 5′-ttcacagatagggcactggac-3′ (rev), for
TRPC3 were 5′-ggtgaactgaaagaaatcaagca-3′ (fw) and 5′-cgtcg
cttggctcttatctt-3′ (rev), for TRPC4 were 5′-aaacttttggttcagaaagg
tgtc-3′ (fw) and 5′-acagttacagcggacctcgt-3′ (rev), for TRPC5 were
5′-ggcgatgcattactctacgc-3′ (fw) and 5′-gctaagcagaagttccacagc-3′
(rev), for TRPC6 were 5′-aggcaaaaggttagcgacaa-3′ (fw) and
5′-ggcataaaagtcatcttgctgaa-3′ (rev), for TRPC7 were 5′-aatgg
cgatgtgaacttgc-3′ (fw) and 5′-gtttgattcggctcagacttg-3′ (rev), for
Cxcc1 5′-TAGTGCCGACCGCTGACT-3′ (fw) and 5′-GGCCT
CTCCCCTAACTGAAT-3′ (rev), for Aip 5′-ACCAGTCATC
CACCAAGAGG-3′ (fw) and 5′-AGGCGATGGCGTCATAGTA-
3′, for H3f3a 5′-GCCATCTTTCAATTGTGTTCG-3′ (fw) and
5′-AGCCATGGTAAGGACACCTC-3′ (rev).
Calcium Imaging
For the measurements of the intracellular free Ca2+
concentration ([Ca2+]i) cells were pre-loaded with a ratiometric
calcium sensitive dye, Fura-2. For this purpose the cells were
incubated 30min at room temperature in Physiological Salt
Solution (PSS) supplemented with 2.5µM Fura-2 acetoxymethyl
ester. PSS composition was (in mM): NaCl 135; KCl 6; MgCl2
1.2; CaCl2 2; HEPES 10; glucose 12. The cells were mounted
on the stage of an inverted Fluorescence microscope Axio
Observer-A1 (Zeiss Jena, Germany) equipped with 40x Fluar oil
Objective (Zeiss, Germany) and imaged using a CCD camera
Axiocam MRm5 (Carl Zeiss GmbH, Germany). Cytoplasmic
Fura-2 was excited using a light source, Lambda DG-4 Plus
(Sutter Instrument, USA). Fluorescence signal was measured at
510 nm during alternate excitation at 340 and 380 nm. The Light
Source and the camera were controlled by the Axiovision 4.8.2
software (Zeiss, Germany) through synchronization interface
SVB-1 (Zeiss, Germany). After correction for the background
fluorescence signals, the fluorescence ratio (F340/F380)
was analyzed using Origin (8.5) software (Northampton,
USA). For antigen stimulation experiments the PMC were
pretreated over night with 300 ng/ml anti-DNP IgE. Experiments
were performed at 22–25◦C. Ca2+ imaging experiments
in Figures 4C–H and Figures 4I–N were performed at
different Ca2+ imaging setups with different light sources
and optical properties of the setups. Therefore, the amplitudes
of F340/F380 ratios obtained in Trpc1/4−/− DKO PMC vary
accordingly and cannot be directly compared between the two
sets of experiments.
Electrophysiological Experiments
Transmembrane currents were measured using EPC- 10 (HEKA
Elektronik, Lambrecht, Germany) “patch-clamp” amplifier in
the whole-cell configuration. The ramp protocol consisted of
a 400-ms ramp from −100 to +100mV (holding potential of
0mV) applied at 0.5Hz. Recordings were started immediately
after achievement of whole-cell configuration. The standard
extracellular solution for patch-clamp contained in mM: NaCl
135; KCl 6; CaCl2 2; MgCl2 1.2; glucose 12; HEPES 10; pH
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FIGURE 1 | Comparison of [Ca2+]i rise induced by different agonists in BMMC and PMC. Measurements of [Ca
2+]i changes performed with Fura-2 and presented as
F340/F380 fluorescence ratio in BMMC (A,C,E,G,I,K) and PMC (B,D,F,H,J,L) isolated from WT mice. Representative traces (n = 20 each panel) of [Ca2+]i changes
(error bars indicate S.E.M.) induced by application of: 10µM Adenosine (Ad) and subsequently DNP (100 ng/ml) (A–D), 100 nM Endothelin-1 (ET-1) (E–H), 200 nM
LTC4 (I–L). The measurements were performed in 3–5 independent cell preparations. At the end of recordings, control reactions were elicited by application of 10µM
adenosine (Ad) (I,K).
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FIGURE 2 | [Ca2+]i rise induced by Mrgprb2 agonists in BMMC and PMC. Measurements of [Ca
2+]i changes performed with Fura-2 and presented as F340/F380
fluorescence ratio in BMMC (A,C,E,G) and PMC (B,D,F,H–L) isolated from WT mice. Representative traces (n = 20 each panel) of [Ca2+]i changes (error bars indicate
S.E.M.) induced by application of: 50µg/ml Compound 48/80 (A–D), 30µg/ml Tubocurarine (E–H), 3µM LL-37(I,K), 10µM Substance P (J,L). The measurements
were performed in 3–5 independent cell preparations. At the end of recordings, control reactions were elicited by application of 10µM adenosine “Ad” (E,G,J,L) or by
application of 50µM Compound 48/80 “Cmp” (I,K).
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FIGURE 3 | Degranulation induced by Mrgprb2 agonists in BMMC and PMC in comparison with other established mast cell activators. Degranulation of BMMC (A,C)
or PMC (B,D) isolated from wild type C57Bl6/N mice was measured using β-hexosaminidase release assay and presented as % of degranulation. Five (A,C) and six
(B,D) independent preparations were measured. The PMC were stimulated with: vehicle solution (SD- spontaneous degranulation), 10µM of ionomycin (Iono),
10 ng/ml DNP (DNP10), 30 ng/ml DNP (DNP30), 100 ng/ml DNP (DNP100), 300 ng/ml DNP (DNP300), 10µM Adenosin (AD), 100 nM Endothelin−1 (ET-1), 10µM
Substance P (SP), 10µM Sphingosine-1-phosphate (S1P), 10µM Lysophosphatidylcholine (LPC), 200 nM Leukotriene C4 (LTC4), 50µg/ml Compound 48/80
(48-80), 30µg/ml Tubocurarine (d-TC), 3µM LL-37 (LL-37), 500µM Chloroquine (CHQ), 300µM L-Carnosine (L-Car).
7.4, with NaOH. Na+ and Ca2+-zero extracellular solution
contained in mM: NMDG 135; KCl 6; MgCl2 1.2; glucose
10; HEPES 10; pH 7.4 (with HCl). The pipette solution
for whole-cell measurements contained in mM: CsCl 80;
MgATP 1; creatine 5; glucose 5; HEPES 10; BAPTA [1,2-bis(2-
aminophenoxy) ethane-N,N,N,N-tetraacetic acid] 10; CaCl2 4.6;
pH 7.4 (with CsOH).
Beta-Hexosaminidase Release PMC
Degranulation Assay
PMC were centrifuged at 300 × g for 5min and re-suspended
in Tyrode solution containing in mM: NaCl 130; KCl 5;
CaCl2 1.4; MgCl2 1; glucose 5,6; HEPES 10, 0,1% Bovine
Serum Albumine (Fraction V); pH 7.4 (with NaOH). The cells
were seeded in a V-bottom 96-well plate (2 × 105 cells/well).
All experimental conditions were performed in duplicates.
Degranulation was induced by incubation of PMC in the
presence of the agonists during 45min at 37◦C and 5% CO2.
Cells were centrifuged at 300 g for 5min at 4◦C. The supernatants
were separated and the cell pellets were lysed in Tyrode solution
supplemented with 1% Triton-X 100 during 5min at room
temperature. The amount of released β-hexosaminidase enzyme
was quantified by spectrophotometric analysis of 4-Nitrophenyl
N-acetyl-β-D-glucosaminide (pNAG) hydrolysis, as previously
described (29). In short, the cell lysates and supernatants were
incubated separately with 2mM pNAG for 1 h at 37◦C and
the reaction was stopped by adding 200mM glycine (pH 10.7
with NaOH). Hydrolysis rate of pNAG was quantified by
colorimetric measurements at 405 nm using the NanoQuant
Infinite M200pro (Tecan, Switzerland) spectrophotometer.
For the background correction the 630 nm absorbance was
subtracted from the 405 nm absorbance values. The percentage
β- hexosaminidase release was calculated as the absorbance ratio
of the supernatant to the sum of supernatant and lysate. If not
stated otherwise, all chemicals used in this work were purchased
from Sigma.
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FIGURE 4 | (A) RT-qPCR expression analysis of Trpc transcripts in PMC. Cq values (mean ± S.E.M.) were obtained from duplicates of 3 independent wild type PMC
preparations. (B) RT-qPCR end products are visualized by agarose gel (2%) electrophoresis. The amplicons correspond to the calculated sizes: Trpc1- (65 bp), Trpc2-
(87 bp), Trpc3- (75 bp), Trpc4- (60 bp), Trpc5- (63 bp), Trpc6- (61 bp), Trpc7- (64 bp), H3f3a - (90 bp), Aip - (86 bp), Cxcc1 - (66 bp). (C–H) Measurements of [Ca2+]i
changes performed with Fura-2 presented as F340/F380 fluorescence ratio in PMC isolated from WT (C57Bl6/N, black) and Trpc1/4−/− (DKO) mice (backcrossed
(Continued)
Frontiers in Immunology | www.frontiersin.org 7 April 2020 | Volume 11 | Article 564
Tsvilovskyy et al. Trpc Channels in Mast Cells
FIGURE 4 | for seven generations on a C57Bl6/N background, blue). Representative traces (n = 20) of [Ca2+]i changes induced by application of 100 ng/ml DNP
(C,D) or 50µg/ml Compound 48/80 (F,G) as indicated by horizontal bars. Mean values of [Ca2+]i changes (error bars indicate S.E.M.) induced by application of
100 ng/ml DNP (E) or 50µg/ml Compound 48/80 (H). For the statistical analysis an average of mean traces obtained from 4 independent preparations was
calculated. In each preparation at least 200 cells were imaged and analyzed. (I–N) Measurements of [Ca2+]i changes performed with Fura-2 and presented as
F340/F380 fluorescence ratio in PMC isolated from Trpc1/4/6−/− (TKO) mice (red) and Trpc1/4−/− (DKO) littermates (genotype Trpc1/4−/−; Trpc6+/+, blue) and.
Representative traces (n = 20) of [Ca2+]i changes induced by application of 100 ng/ml DNP (I,J) or 50µg/ml Compound 48/80 (L,M) as indicated by horizontal bars.
Mean values of [Ca2+]i changes (error bars indicate S.E.M.) induced by application of 100 ng/ml DNP (K) or by application of 50µg/ml Compound 48/80 (N). For the
statistical analysis an average of mean traces obtained from 5 (K) to 6 (N) independent preparations was calculated. In each preparation at least 200 cells were
imaged and analyzed.
Statistics
For statistical analysis, Origin 8.5 (Northampton, USA) and
Microsoft Excel 2010 software were used. For the determination
of significant differences of mean values obtained from two
groups, a two-sample Student’s t-test was used (p < 0.05 for
significance). n indicates the number of individual experiments
unless otherwise stated.
RESULTS
Comparison of Ca2+-Dependent MC
Activators
We have compared the ability of well-known secretagogues to
elevate [Ca2+]i in BMMC and PMC. Application of Adenosine
(10µM) with the subsequent application of the antigen DNP
(100 ng/ml) as previously described (30) led to a typical
biphasic reaction with comparable amplitudes evoked by either
agonist in both BMMC and PMC (Figures 1A–D). Acute
application of Endothelin 1 (100 nM) evoked a transient response
of high amplitude only in some BMMC (Figure 1E). The
probability of response to the second application of Endothelin-
1 (100 nM) in BMMC was much lower in comparison to the
first one (Figure 1E). In contrast to BMMC, acute application
of Endothelin-1 evoked a massive synchronized response of
high amplitude in all tested PMC (Figure 1F). The removal of
the agonist as well as the recurrent application of the same
agonist concentration showed no visible effect (Figure 1F). In
average, Endothelin-1 evoked a much more pronounced rise in
[Ca2+]i in PMC in comparison to BMMC (Figures 1G,H). It is
published, that activation of cysteinyl leukotriene type I (cysLT1)
receptors with Leukotriene C4 (LTC4, 160 nM) in RBL2H3 cells
evokes a series of oscillations in [Ca2+]i involving calcium release
activated Ca2+ influx (31). We tested LTC4 (200 nM) in both
BMMC and PMC but did not observe any rise in [Ca2+]i
(Figures 1I–L).
Testing of the Ca2+ Mobilizing Ability of
Mrgprb2 Receptor Agonists in BMMC and
PMC
Acute application of the Mrgprb2 receptor agonist Compound
48/80 (50µg/ml) evoked a delayed oscillatory non-synchronous
[Ca2+]i elevation in BMMC which did not return to the baseline
after the agonist removal. A second application of the agonist
elicited an additional [Ca2+]i elevation (Figures 2A,C). In PMC,
acute application of Compound 48/80 (50µg/ml) evoked an
immediate, synchronous and prominent [Ca2+]i elevation which
also did not get back to baseline levels after the agonist removal.
In contrast to BMMC, a second application of the agonist did
not elicit an additional [Ca2+]i elevation (Figures 2B,D). Based
on this robust [Ca2+]i rise evoked by Compound 48/80, we
tested other Mrgprb2 receptor agonists. Acute application of
Tubocurarine (30µg/ml) evoked an immediate and prominent
[Ca2+]i elevation in BMMC which was not observed in all
tested cells (Figures 2E,G). In PMC, acute application of
Tubocurarine (30µg/ml) evoked an immediate synchronous
prominent [Ca2+]i elevation which was observed in all tested
cells (Figures 2F,H).
Acute application of LL-37 (3µM), which is an antimicrobial
peptide known to activate Mrgprb2 receptors (32), evoked an
immediate synchronous [Ca2+]i elevation in PMC which was
observed in all tested cells (Figures 2I,K). In contrast, application
of LL-37 (3µM) evoked no significant [Ca2+]i elevation in
BMMC (Figures S1A,B).
Acute application of Substance P (10µM), which can activate
MRGPRX2 receptors (33) in addition to NK receptors (34),
evoked an immediate synchronous prominent [Ca2+]i elevation
in PMC, which was observed in all tested cells. A second
application of the agonist did not elicit a significant [Ca2+]i
elevation (Figures 2J,L). In BMMC, an acute application of
Substance P (10µM) did not evoke a significant elevation of the
[Ca2+]i (data not shown).
Acute application of the dipeptide L-Carnosine (β-Alanyl-l-
histidine) can activate Mrgprd receptors (35) and β-Alanin was
reported to activate primary sensory neurons (36). We tested the
effect of L-Carnosine in both mast cell types, and found that
application of L-Carnosine (1µM followed by 10µM) evoked
no significant [Ca2+]i elevation in BMMC (Figures S1C,E). Also
in PMC, no significant [Ca2+]i elevation was observed following
application of either 1 or 10µMof L-Carnosine (Figures S1D,F).
Analysis of Degranulation Evoked by
Mrgprb2 Receptor Agonists in Comparison
With Other Mast Cells Secretagogues in
BMMC and PMC
Among the Mrgprb2 receptor agonists used in the Ca2+
imaging experiments we have observed degranulation reactions
in BMMC, which were significantly higher compared to
spontaneous degranulation after stimulation with 10–300 ng/ml
DNP, 10µM Adenosine, 50µg/ml Compound 48/80, and
30µg/ml Tubocurarine. Degranulation reaction was negligible
in response to 100 nM Endothelin-1, 10µM Substance P, 10µM
Sphingosine-1-phosphate, 10µM Lysophosphatidylcholine,
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FIGURE 5 | Compound 48/80-induced whole-cell transmembrane currents (A–E) and degranulation (F) in PMC isolated from TRPC-deficient mice. (A)
Representative time course of the amplitude of inward (dark blue) and outward (blue) currents measured at −50 and +50mV, respectively in PMC isolated from
Trpc1/4−/− (DKO) mice (DKO, genotype Trpc1/4−/−; Trpc6+/+). The currents were elicited by acute application of Compound 48/80 (50µg/ml) as indicated by
horizontal bar. (C) Representative time course of the amplitude of inward (red) and outward (pink) currents measured at −50 and +50mV, respectively in PMC isolated
from Trpc1/4/6−/− (TKO) mice. The currents were elicited by acute application of Compound 48/80 (50µg/ml) as indicated by horizontal bar. Current amplitude is
normalized to the cell capacitance and presented as pA/pF. (B) Representative current-voltage relationship curves measured in PMC isolated from wild type (WT,
gray), Trpc1/4−/− (DKO, genotype Trpc1/4−/−; Trpc6+/+, blue) and from Trpc1/4/6−/− (TKO) mice (red). The curves correspond to the measurements presented in
(A,C) at the current’s maximal values. (D) Statistical bar diagrams of the maximal current density measured at +50/−50mV (left panel) and at +100/−100mV (right
panel) shows the mean (vertical bars) and S.E.M. (error bars) values calculated for PMC isolated from WT (gray and black bars) Trpc1/4 double deficient (blue and dark
blue) and Trpc1/4/6 deficient (pink and red bars) mice. The measurements were performed with PMC originating from three independent preparation and 15–20
individual cells were analyzed. Horizontal bars indicate significance (**p < 0.01 and ***p < 0.001). (E) Representative time course of the amplitude of inward (dark blue)
and outward (blue) currents measured at −50 and +50mV, respectively in PMC isolated from Trpc1/4−/− (DKO) mice. Compound 48/80 was applied in Ca2+- and
Na+-free external solution in concentration 50µg/ml as indicated by horizontal bar. (F) Degranulation of PMC measured using ß-hexosaminidase release assay and
presented as % of degranulation. PMC were isolated from Trpc1/4−/− (DKO) mice (blue bars) and Trpc1/4/6−/− (TKO) (red bars) mice and stimulated with different
concentrations of Compound 48/80 (Cmp). Positive (IM: −10µM of ionomycine) and negative controls (spont- spontaneous release) were also measured.
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200 nM Leukotriene C4, 3µM LL-37, 500µM Chloroquine, and
300µM L-Carnosine, respectively (Figures 3A,C). Stimulation
with Ionomycin (10µM) served as a control.
In PMC, we found degranulation reactions significantly
higher than those occurring spontaneously after stimulation with
10–300 ng/ml DNP, 100 nM Endothelin-1, 50µg/ml Compound
48/80, 30µg/ml Tubocurarine, 3µM LL-37, and 500µM
Chloroquine. Degranulation reactions were negligible after
application of 10µM Adenosine, 10µM Substance P, 10µM
Sphingosine-1-phosphate, 10µM Lysophosphatidylcholine,
200 nM Leukotriene C4, and 300µM L-Carnosine, respectively
(Figures 3B,D).
Based on these results we can conclude that BMMC exhibit
an increased degranulation response compared to PMC following
stimulation with 10µMAdenosine (p= 0.007), and PMC exhibit
a larger response to 100 nM Endothelin-1 (p = 8e-07) and
500µMChloroquine (p= 0.001). The Mrgprb2 receptor agonist
Compound 48/80 evoked similar extents of degranulation in both
PMC and BMMC.
Analysis of TRPC Expression in PMC
We studied the expression of transcripts encoding TRPC channel
proteins by RT-qPCR in PMC. As shown in Figure 4A, all TRPCs
transcripts are detected in PMC, with Trpc2, Trpc4, Trpc6, Trpc7
transcripts being more abundant compared to Trpc1, Trpc3, and
Trpc5. The relative expression is presented as Cq values which
are reverse proportional to the level of expression. Endpoint PCR
products were visualized by gel electrophoresis and amplicons of
the expected size were obtained (Figure 4B).
Partial Contribution of TRPC Channels to
[Ca2+]i Elevation Elicited by Mrgprb2
Receptor Stimulation in PMC
From former experiments using PMC from various Trpc
knockout mouse lines we had evidence that Ca2+ elevation
evoked by several agonists were reduced in mast cells of
Trpc1/4/5/6−/− quadruple knockout mice (37), as well as
inTrpc1/4/6−/− triple and Trpc1/4−/− double knockout mice.
The mast cells for these experiments had been isolated from
mouse lines on a mixed C57Bl6/N × 129SvJ genetic background
and compared to PMC of mice from the F1 generation of
C57Bl6/N × 129SvJ matings as controls (data not shown).
However, when we analyzed calcium transients measured in
PMC from Trpc1/4−/− double knockout (DKO) mice on
C57Bl6/N background (mated from Trpc1−/− and Trpc4−/−
single knockout mice after 7 generation backcrossing) we found
that [Ca2+]i elevation evoked by FcεRI stimulation by acute
application of DNP (100 ng/ml) was statistically not significantly
different compared to those in PMC isolated from C57Bl6/N
wild type controls (Figures 4C–E). Similarly, Ca2+ transients
observed in PMC in response to acute application of 50µg/ml of
Compound 48/80 were also statistically not significantly different
in PMC isolated from Trpc1/4−/− DKO mice in comparison to
C57Bl6/N wild type PMC (Figures 4F–H).
Since the responses to FcεRI and Mrgprb2 receptor
stimulation were identical in PMC from Trpc1/4−/− DKO
and WT mice, we then compared PMC from Trpc1/4/6−/−
(TKO) knockout mice and used littermatched Trpc1/4−/− DKO
mice as controls (see methods for breeding scheme). Calcium
transients evoked in PMC in response to acute application
of DNP (100 ng/ml) were statistically not significantly
different in PMC isolated from Trpc1/4/6−/− (TKO) mice
or Trpc1/4−/− DKO mice (Figures 4I–K). In contrast, peak
calcium transients evoked in response to acute application
of Compound 48/80 (50µg/ml) were significantly lower (by
24%) in PMC from Trpc1/4/6−/− (TKO) mice in comparison
to those in PMC isolated from Trpc1/4−/− (DKO) mice
(Figures 4L–N). The AUC of the Ca2+ transients was reduced
by 20 % in average.
Characterization of Compound
48/80-Induced Currents in PMC
To study Compound 48/80-induced transmembrane ionic
currents in PMC we applied the standard patch clamp voltage
clamp technique in the whole-cell configuration. The cells were
perfused with Cs+-based pipette solution to block K+ channels,
and [Ca2+]i was strongly buffered at a concentration close to
100 nM. A standard external physiological salt solution was
used for these experiments. The cells were kept at a holding
potential of 0mV and periodical 400ms depolarizing ramp
pulses (−100 to +100mV) were applied at a frequency of
0.5Hz. In response to external application of Compound 48/80
(50µg/ml) we observed a slowly developing current, which
reached a plateau phase after 1–2min and showed an almost
linear current-voltage relationship and a reversal potential near
0mV (Figures 5A,B). Agonist removal led to gradual reduction
of the current which returned almost to the basal level during
1–3min (Figure 5A). These currents were observed in PMC
isolated from WT (C57Bl6/N, black bars in Figure 5D) as well
as from Trpc1/4−/− (DKO) mice, and their amplitude was
not different in PMC of these two genotypes. However, the
additional deletion of TRPC6 proteins in PMC of Trpc1/4/6−/−
(TKO) mice significantly decreased the amplitude of the inward
and outward currents compared to PMC from Trpc1/4−/−
(DKO) or C57Bl6/N mice as indicated in representative traces
(Figure 5C) and in the statistical analysis performed at +50,
−50, +100, −100mV (Figure 5D). The current in PMC from
Trpc1/4−/−DKO mice was also almost entirely abolished if
an extracellular solution lacking Na+ and Ca2+ ions was
used (Figure 5E).
Participation of TRPC6 in Compound 48/80
Induced Degranulation in PMC
A β-hexosaminidase assay was performed in PMC of
Trpc1/4/6−/− (TKO) knockout mice and litter-matched
Trpc1/4−/− DKO mice. Whereas, no difference in degranulation
was observed when the cells were stimulated with 50µg/ml
and 10µg/ml Compound 48/80, the measurements revealed
a significant reduction (28% in average) of Compound 48/80-
induced degranulation in PMC lacking TRPC1/TRPC4/TRPC6
proteins when a concentration of 1µg/ml of Compound 48/80
was used (Figure 5F).
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DISCUSSION
In this study we comparatively analyzed numerous secretagogues
in two primary murine mast cell (MC) models: peritoneal
mast cells (PMC), as an example of connective tissue type
MC (CTTMCs) (38), and bone marrow-derived and in vitro
matured mast cells (BMMC) (39) which belong to the mucosal
type MCs (MMCs). We provide experimental evidence for at
least a partial contribution of TRPC channel proteins to Ca2+-
dependent mast cell activation in PMC evoked by the Mrgprb2
agonist Compound 48/80.
Characteristics of CTTMC and MMC Mast
Cell Models
With a comparative analysis of two culture-matured and tissue-
derived mast cell models we aimed to functionally evaluate the
suitability of these primary mast cells for the analysis of Ca2+-
dependent mast cell activation in vitro. The main difference
between the connective tissue and mucosal type mast cells is
the variety of proteases they express. Thus, mature connective-
tissue mast cells express chymases known as mouse mast-
cell protease-4 (MMCP-4), -5, and -2, as well as tryptases
MMCP-6 and -7, and carboxypeptidase A. Mast cells of the
mucosal type preferentially express proteases such as MMCP-
1 and -2 as seen in rat mast cells (40, 41). In addition,
connective-tissue-type mast cells express little or no NDST-1(N
-deacetylase/N -sulphotransferase-2), but contain large amounts
of the transcript encoding NDST-2 (42). It is also known that
PMC express a wider range of Toll-like receptors (TLRs), and
secrete significantly more cytokines in response to TLR ligand
stimulation compared to BMMC or to immortalized mast cell
lines (43). The expression of distinct proteases can be well
illustrated by the fact that Mcpt5-Cre (mast-cell protease-5)
transgenicmice enable gene inactivation only in connective tissue
mast cells but not in mucosal mast cells (44). In contrast to
extensive characterization of connective tissue and mucosal type
mast cells with respect to their enzymatic repertoire, there is
very little information regarding their responses to the numerous
published Ca2+ mobilizing mast cell activators. In particular,
the activity of these Ca2+ mobilizing mast cell activators has
not been comparatively characterized in BMMC and PMC as
the two primary murine mast cell models (12, 45), which were
studied very frequently after gene-deficient mouse lines became
increasingly available.
Features of the Agonist-Evoked Ca2+ Rise
in BMMC and PMC
An elevation of the [Ca2+]i in mast cells, which is a key
signal for mast cell activation, can be triggered not only
by activation of Fcε receptor for IgEs (FcεRI) with antigens
but has also been reported after exposure to numerous
agonists such as adenosine, Endothelin-1 (ET-1), Leukotriene
C4 (LTC4), lysophosphatidylcholine (LysoPC), sphingosine-1-
phosphate (S1P) or Substance P and even others (14). In
our study we found that, whereas antigen stimulation of
FcεRI was similarly effective in triggering [Ca2+]i elevations
in PMC and BMMC, other agonists including Endothelin-1
(ET-1, 100 nM) evoked much more prominent responses in
PMC in comparison to BMMC or did not evoke any [Ca2+]i
rise in either mast cell model. As expected, the magnitude of
[Ca2+]i rise correlated with extent of mast cell degranulation.
Similar results were obtained in a comparison of Endothelin-
1 (ET-1)-induced degranulation in fetal skin-derived cultured
mast cells (FSMCs) and BMMC, as ET-1 induced degranulation
in FSMC but not in BMMC (46). The cysteinyl leukotriene
receptor I (cysLT1) agonist, leukotriene C4, did not produce
any [Ca2+]i rise or degranulation response neither in BMMC
nor in PMC at least in the concentration of 200 nM. This is
in contrast to published data that show that LTC4 (160 nM)
is quite effective in producing [Ca2+]i rise in other mast cell
models such as RBL2H3 cells (31). Notably, LTC4 plays a central
role in activation of human nasal polyp–derived mast cells in
a paracrine way (47). Obviously, murine BMMC and PMC are
not suitable models to study Ca2+ dependent mast cell function
that are evoked by Cysteinyl leukotriene receptors and triggered
by LTC4.
Mrgprb2-Mediated Ca2+ Signaling in
BMMC and PMC
Compound 48/80 is well-known as a Ca2+-dependent mast
cell activator for years, but the receptor mediating Ca2+ entry
and mast cell activation by this agonist and a range of other
cationic substances termed basic secretagogues was identified
in 2015 (4). We found that the Mrgprb2 agonist Compound
48/80 evoked a significant [Ca2+]i rise and degranulation
response in PMC and BMMC, but these responses were much
weaker in BMMC. Other agonists of Mrgprb2 receptors such
as Tubocurarine or LL-37 and Chloroquine, which are reported
to activate other Mrgpr receptors (48), demonstrated a similar
relation regarding their action in BMMC vs. PMC suggesting
that the expression level or coupling of Mrgprb2 receptors or
of the signaling molecules downstream differs between these
two types of mast cells. Substance P evoked a [Ca2+]i rise
only in connective tissue type PMC and did not produce any
significant degranulation in these cells. The functional target of
Substance P in PMC and mast cells in general is not clearly
defined. Substance P is able to activate the human ortholog
of Mrgprb2, MRGPRX2 (33), but not the mouse Mrgprb2
receptor (49). In addition, Substance P is also capable of
stimulating NK receptors (34) which are also expressed in TC
mast cells (50).
In general, our data demonstrate a much higher efficiency
of Mrgpr agonists in PMC to induce [Ca2+]i elevation and
degranulation in comparison to BMMC. These results are
in agreement with those of a previous report, in which it
has been shown that Mrgprb2 is specifically expressed on
connective tissue mast cells but not on mucosal mast cells in
mice (4).
Contribution of TRPC Channels to
Mrgprb2-Mediated Ca2+ Rise in PMC
Our expression analysis revealed that transcripts of all members
of the TRPC family of transient receptor potential (TRP)
Frontiers in Immunology | www.frontiersin.org 11 April 2020 | Volume 11 | Article 564
Tsvilovskyy et al. Trpc Channels in Mast Cells
channels could be detected in PMC. Since we had evidence
that Ca2+ elevation evoked by various agonists leading to
Phospholipase C activation were reduced in PMC mast cells
of Trpc1/4/5/6−/− quadruple knockout mice (37) and also
Trpc1/4/6−/− triple knockout mice both on a mixed C57Bl6/N×
129SvJ genetic background compared to PMC of corresponding
wild type control mice, we subsequently studied Trpc1/4/6−/−
mice that were obtained after seven generation of backcrosses
into the C57Bl6/N background, which were then compared
to littermatched Trpc1/4−/− controls (see Methods for details
of breeding). We found that FcεRI-mediated Ca2+ rise was
not significantly different in PMC from Trpc1/4/6−/− mice
compared to PMC from either C57Bl6/N or Trpc1/4−/−
littermatched controls indicating the importance of the genetic
background for studies evaluating Ca2+ signaling in murine
PMC mast cells. Nevertheless, Compound 48/80-evoked [Ca2+]i
transients were reduced by ∼20% in PMC from Trpc1/4/6−/−
mice which goes along with the abrogation of Compound
48/80-evoked cation currents and an according reduction of
mast cell degranulation. In the past, many studies about the
role of TRPC channels in mast cells have been performed
using immortalized mast cell lines (14). There are only a
few reports about the role of TRPC channels and particularly
TRPC1, TRPC4, and TRPC6 in mast cell activation. Altered
calcium responses in Lyn-deficient mast cells are at least
partially attributed to a Lyn-dependent role in maintaining
basal expression of Trpc4 (51). In BMMC from TRPC1
knockout mice, an unexpected increase in antigen-evoked
interleukin and TNFα secretion was reported (52). TRPC1
and TRPC6 were found to be expressed in human mast cell
lines, but a contribution of Orai and not TRPC channels to
FcεRI-mediated calcium signaling was demonstrated recently
(53). These data are similar to our findings showing that
TRPC6 plays a significant role specifically in Mrgprb2- but
not FcεRI-mediated [Ca2+]i elevation in murine PMC. In
murine mast cells the Orai1 knock out (54, 55) and knock
down of Orai1 in human lung mast cells (56) reduced FcεRI-
mediated calcium rise and FcεRI-dependent mediator release,
respectively, whereas these responses was increased in PMC of
Orai2 knock out mice (57).
Our study shows that in PMC from Trpc1/4/6−/− mice
the FcεRI-mediated Ca2+ rise is unchanged and Mrgprb2-
mediated Ca2+ rise is partially reduced. The signaling events
downstream of Mrgprb2 receptor activation that specifically
engage these TRPC channels remain unclear, but it needs to
be mentioned that there is a growing experimental evidence of
important differences between MRGPRX2- and FcεRI-mediated
mast cell activation and degranulation (17). Notably, FcεRI-
mediated mast cell activation involves a robust inflammatory
reaction by synthesis of cytokines and chemokines, and this
reaction has been shown to be limited in MRGPRX2-mediated
activation (17). Classically, IgE-dependent mast cell activation
occurs via FcεRI with the subsequent tyrosine phosphorylation
of multiple proteins including phospholipase Cγ1 the activation
of which leads to multiple downstream events including an
increase in cytosolic calcium levels. There is evidence that
Mrgpr activation involves activation of phospholipase C which
leads to DAG formation. For example, beta-defensins are
proinflammatory pruritogens that activate Mrgprs (58) and act
chemotactic for mast cells through a pertussis toxin-sensitive
and phospholipase C-dependent pathway (59). Diacylglycerol
(DAG) formed by phospholipase C could be a signal activating
TRPC3/6 channels (60) also in the plasma membrane of
mast cells.
The molecular constituents of the channels engaged following
Mrgprb2 receptor activation have not been identified. However,
it was reported already long time ago that Compound 48/80
activates a Ca2+ influx in rat peritoneal mast cells (17). One type
of channel responsible for the Ca2+ influx followed Compound
48/80 stimulation is voltage–independent and has a relatively low
selectivity for Ca2+ over Na+ (19–21), which closely resembles
the properties of agonist-operated TRPC cation channels. In our
study in PMC we observed Compound 48/80–induced currents
using patch-clamp recordings. These currents exhibited a nearly
linear current-voltage relationship with a reversal potential close
to 0mV resembling typical TRPC-mediated currents described in
numerous cell models (61). This current was almost absent when
an external solution lacking both Ca2+ and Na+ ions was used
demonstrating the cationic nature of Compound 48/80–induced
currents. This current was strongly reduced in PMC from
Trpc1/4/6−/− mice implying that the Compound 48/80-induced
Ca2+ elevation might be attributed to the Ca2+ influx through
TRPC6-containing channels in murine PMC. The contribution
of TRPC6 to the compound 48/80-evoked current was elaborated
by genetic deletion of TRPC6 expression. The deduced concept
of TRPC6 as an indispensable constituent of cation channels
activated by compound 48/80 in PMCs could be corroborated
in future studies by experimental evidence showing that acute
blockage of these currents using TRPC6-specific antagonists
such as Pyrazolo [1,5-a] pyrimidines antagonist (62) or BI
749327 (63).
Taken together, our data revealed that PMC are an
appropriate mast cell model to study mechanisms of
Mrgprb2 receptor-mediated mast cell activation and that
TRPC proteins contribute at least partially to the activation of
PMC evoked by stimulation of Mrgprb2 receptors. However,
the channels conducting most of the Ca2+ entry triggered
by Mrgprb2 receptor stimulation still remain unknown.
PMC express plenty of Ca2+-permeable cation channels.
We have recently excluded a significant participation of
TRPV1, TRPV2, and TRPV4 channels in both FcεRI- and
Mrgprb2- mediated activation of PMC (64). At the same
time Orai1, Orai2, and Orai3 proteins are abundantly
expressed in PMC, and at least Orai2 has a critical role in
receptor- and store-operated Ca2+entry in murine PMC
(57), whereas the contribution of Orai1 and Orai3 proteins
in Mrgprb2-evoked mast cell activation in general remains
to be identified.
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Figure S1 | Mrgprb2 agonists without Ca2+ mobilizing effects in BMMC or PMC
murine mast cells. Measurements of [Ca2+]i changes performed with Fura-2 and
presented as F340/F380 fluorescence ratio in BMMC (A–C,E) and PMC (D,F)
isolated from WT mice. Representative traces (n = 20 each panel) of [Ca2+]i
changes (error bars indicate S.E.M.) induced by application of 3µM of LL-37
(A,B), 1µM L-Carnosine (C,E), and 10µM of L-Carnosine (D,F). The
measurements were performed in 3–5 independent cell preparations. At the end
of recordings, control reactions were elicited by application of 10µM adenosine
“Ad” (A–C,E) or by application of 50µM Compound 48/80 “Cmp” (D,F).
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